Hepatitis C cirrhosis: New perspectives for diagnosis and treatment

Table 3 The recommended for treatment of hepatitis C virus infection by genotype in treatment-naïve patients and in treatment naïve patients with compensated cirrhosis[22]

Genotype	Recommended regimen and duration	Recommended regimen for compensated cirrhosis (CP-A) and duration
1a	Three options with similar efficacy:	Three options with similar efficacy:
	(1) Daily fixed dose LDP (90 mg)/SOF (400 mg) for 12 wk	(1) Daily fixed dose LDP (90 mg)/SOF (400 mg) for 12 wk
	(2) Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk	(2) Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk
	(3) Daily SOF (400 mg) plus SMV (150 mg) with or without weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk	(3) Daily SOF (400 mg) plus sMV (150 mg) with or without weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 24 wk
1b	Three options with similar efficacy:	Three options with similar efficacy:
	(1) Daily fixed dose LDP (90 mg)/SOF (400 mg) for 12 wk	(1) Daily fixed dose LDP (90 mg)/SOF (400 mg) for 12 wk
	(2) Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) for 12 wk	(2) Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk
	(3) Daily SOF (400 mg) plus SMV (150 mg) with or without weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for12 wk	(3) Daily SOF (400 mg) plus SMV (150 mg) with or without weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 24 wk
2	SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk	SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 16 wk
3	(1) SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 24 wk
	(2) Alternative for IFN eligible: SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] plus weekly peg IFN for 12 wk
4	Three options with similar efficacy and 2 alternatives available:
	(1) Daily fixed dose LDP (90 mg)/SOF (400 mg) for 12 wk
	(2) Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk
	(3) Daily SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 24 wk
	(4) Alternative 1 for IFN eligible: Daily SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] plus weekly peg IFN for 12 wk
	(5) Alternative 2 for IFN eligible: Daily SOF (400 mg) plus SMV (150 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk
5	(1) Daily SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] plus weekly peg IFN for 12 wk
	(2) Alternative 1 for IFN eligible: Weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] plus weekly peg IFN for 48 wk
6	(1) Daily fixed dose LDP (90 mg)/SOF (400 mg) for 12 wk
	(2) Alternative 1 for IFN eligible: Daily SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] plus weekly peg IFN for 12 wk

LDP: Ledipasvir; SOF: Sofosbuvir; SMV: Simeprevir; Peg IFN: Pegylated interferon alfa-2a; RBV: Ribavirin; CP-A: Child-Pugh class A.